Hengrui Medicine announced that its subsidiaries have received approval from China's National Medical Products Administration for clinical trials of three drugs. These include SHR-3821 for advanced solid tumors, Adebelimumab injection (already approved in 2023), and Rilafuvirt-alpha injection (approved January 2026). Separately, Xiangcai Co. has had its merger review with Dazhihui resumed by the Shanghai Stock Exchange after a previous suspension due to outdated financial data. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON The cluster contains multiple significant corporate announcements including drug trial approvals and a merger review resumption. [lever_c_demoted from significant: ic=1 ai=0.1]